Fomivirsen

Fomivirsen

File:Fomivirsen composite.png
Clinical data
Pregnancy category	B2
Routes of administration	Intravitreal injection
ATC code	S01AD08 (WHO)
Identifiers
CAS Number	160369-77-7
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C204H263N63O114P20S20
Molar mass	6682.4 g/mol

Fomivirsen (brand name Vitravene) is an antiviral drug. It is used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS.

It is an oligonucleotide that blocks translation of viral mRNA by binding to a coding segment of a key CMV gene. It was the first antisense antiviral approved by the FDA.

It is available as an intraocular injection in a concentration of 6.6 mg/ml¹

References

1. Katzung, BG. Basic and Clinical Pharmacology 10th ed., 2007. McGraw-Hill Co., Inc.

See also

• retinitis

External links

• Diagram
• Template:MedlinePlusDrugInfo
• Template:DiseasesDB
• "Fomivirsen". Drugs Today (Barc). 37 (4): 245–255. 2001. PMID 12768225.
• Geary R, Henry S, Grillone L (2002). "Fomivirsen: clinical pharmacology and potential drug interactions". Clin Pharmacokinet. 41 (4): 255–60. PMID 11978144.CS1 maint: Multiple names: authors list (link)
• "Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS". Am J Ophthalmol. 133 (4): 475–83. 2002. PMID 11931781.
• Roehr B (1998). "Fomivirsen approved for CMV retinitis". J Int Assoc Physicians AIDS Care. 4 (10): 14–6. PMID 11365956.